Compare RNTX & FSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | FSI |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 63.7M |
| IPO Year | 2017 | 2000 |
| Metric | RNTX | FSI |
|---|---|---|
| Price | $0.70 | $6.07 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 325.7K | 9.9K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | ★ 44.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $15,494,325.00 |
| Revenue This Year | N/A | $24.09 |
| Revenue Next Year | N/A | $60.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $4.85 |
| 52 Week High | $2.18 | $9.89 |
| Indicator | RNTX | FSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 54.16 |
| Support Level | N/A | $5.95 |
| Resistance Level | $0.87 | $6.11 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.04 | 35.00 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.